SPONSORSVIDEO PLAYER BOTTOM
Auto × Auto
1357 4 days ago
1357 4 days ago
Swedish innovative preservation technology used in the world’s first ever successful heart xenotransplantation (pig to human)
On January 7, 2022, the world’s first ever successful pig to human heart transplantation took place, a groundbreaking milestone for the field of transplantation. A team at the 'University of Maryland School of Medicine, USA, performed the procedure. The recipient was a 57-year-old terminally ill man who received a heart from a gene-modified pig.
After retrieval, the pig heart was preserved with XVIVO’s heart perfusion device and proprietary solution until transplanted.
Organ shortage is the greatest challenge facing the transplant field today. Consequently, only a small number of patients with end stage heart disease is given the opportunity of a transplant and many die while waiting for a new organ. A potential solution to this critical shortage is xenotransplantation, which means transplantation between species.
Groundbreaking research, utilizing XVIVOs heart preservation technology, has in recent years achieved longterm survival after xenotransplants of hearts from gene-modified pigs to primates. Based on this extensive research the first ever transplantation of a heart from a genetically modified pig to a human has now taken place.
The patient did not qualify to receive a conventional human organ transplant, and due to his terminal heart disease, xenotransplant was the only available option for his survival. He is still doing well three days after the historic surgery.
XVIVO has developed a novel method for storing and transporting donated hearts in an optimized way, through non-ischemic heart preservation (NIHP) in collaboration with Professor Stig Steen and Igelösa Life Science in Lund, Sweden. The XVIVO heart perfusion device preserves the donor heart at 8 C˚ while continuously pumping an oxygenated, propriety solution through the organ.
The first transplants with human donors have successfully been performed and several clinical trials at leading transplant centers in Europe and Australia are ongoing. In 2019, XVIVO’s new heart technology was granted ‘Breakthrough Device Designation’ from the U.S. Food and Drug Administration (FDA) and a multicenter clinical trial is planned in the US for 2022.
The new heart preservation technology is intended for clinical human to human transplants, but it has also been demonstrated to be pivotal for long term survival in pre-clinical research using pig hearts for xenotransplantation by mitigating the risk of early organ dysfunction.
You have to be a full member to view the comments section.
Leaked Reality is a private member supported forum. If you would like to join the community,
you can do so by donating/paying a one time fee of $5 to the cost of running the site..
If you'd like to join, please Click here to Support LR
or Click here to Donate to LR